With the Company's patented Nitric Oxide gas generating and delivery system and its proprietary and patented Nitric Oxide micro tablet medium manufacturing technology, the Company has the potential to make a significant and life-changing difference in the clinical use of Nitric Oxide in standardized and accepted clinical treatment practices across the world, initially in the treatment of mutating drug-resistant tuberculosis and Swine Flu (H1N1), Influenza A, and other non-clinical uses.